{
}
The global small-molecule injectable drugs market reached $188.9 billion in 2021, with a projected growth rate of 8% CAGR, expected to hit $837.8 billion by 2030. North America leads the market with a 37% share, driven by increased R&D and product approvals, while Europe is anticipated to grow the fastest due to rising demand for minimally invasive procedures. Intravenous injections accounted for 30% of the market, highlighting their critical role in rapid drug administration.
The bile duct cancer market is expanding, driven by a shortage of specialists and healthcare system challenges in developing countries. In 2021, North America led the market with a 37.1% share and $185.4 billion in revenue, fueled by increased R&D and rising cancer prevalence. The Asia-Pacific region is projected to grow the fastest through 2030, supported by awareness programs and private investments.
The third-quarter earnings season for major drugmakers, including Pfizer, Eli Lilly, AbbVie, Merck, and Bristol Myers Squibb, is underway, with Pfizer expected to report results on Oct. 29. Pfizer has consistently exceeded earnings expectations, with a four-quarter average surprise of 69.82%, despite declining COVID product sales. Overall, the Medical sector anticipates a 3.5% year-over-year earnings increase and an 8.8% revenue growth.
Novartis has entered a $150 million deal with Monte Rosa Therapeutics to develop molecular glue degraders targeting the immune signaling protein VAV1, which is considered "undruggable." The partnership could yield up to $2.1 billion in additional payments based on development milestones. Monte Rosa will complete the ongoing Phase 1 study of MRT-6160, while Novartis will manage further development, with both companies sharing profits and losses from commercialization.
Ottimo Pharma has launched under the leadership of former Seagen CEO David Epstein, focusing on a bi-functional antibody, jankistomig, that targets both PD-1 and VEGFR2 to enhance cancer immunotherapy. The startup aims to initiate its first clinical trial next year, with backing from Medicxi. Epstein emphasizes the drug's potential to significantly benefit patients with various solid tumors, while industry veterans Mehdi Shahidi and James Sabry join the team to drive development and strategy.
David Epstein, the former CEO of Seagen Inc., has launched a new biotech company, Ottimo Pharma, focused on developing a drug that addresses multiple cancer vulnerabilities. This innovative approach includes targeting a protein associated with Merck & Co.'s successful treatment, Keytruda. The company emerged after four years of development in secrecy.
Pfizer reported a net profit of Rs 158.4 crore for Q2 2024, with a revenue increase of 2.3%. Meanwhile, CAMS saw a significant 45% rise in profit after tax, reaching Rs 122.5 crore for the quarter ending September 2024, alongside a 33% growth in revenues from operations to Rs 365.17 crore.
Vaud pharmacists express frustration over low reimbursements for Pfizer vaccines and other medications, which threaten their economic viability, especially in rural areas. They urge Federal Councillor Elisabeth Baume-Schneider to recognize their essential role in healthcare and engage in dialogue to adjust reimbursement rates that reflect the full scope of their services.
Sanofi's third-quarter earnings surged 25% in its vaccines division, driven by strong sales of Beyfortus, its RSV antibody for infants, which generated 645 million euros. Overall, the company reported total sales of $13.4 billion, exceeding Wall Street expectations and reflecting nearly 16% growth. The recent approval of a new manufacturing line aims to enhance Beyfortus supply amid high demand, ensuring access for all eligible infants in the U.S.
The CDC's advisory panel has recommended lowering the routine pneumococcal vaccination age from 65 to 50, potentially expanding the market for vaccines like Merck's Capvaxive and Pfizer's Prevnar. Analysts have adjusted sales forecasts, anticipating significant revenue growth for these vaccines, particularly for Merck in the near term, though competition from Vaxcyte's candidate may emerge by 2028.
Pfizer Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
global small molecule injectable drugs market trends and regional insights 2021
United States Dollar
Pfizer Inc.
Novartis AG
טבע תעשיות פרמצבטיות Ltd.
Aurobindo Pharma Limited
Merck & Co., Inc.
FRA
RUS
GBR
ITA
ESP
USA
KOR
SAU
JPN
MEX
ARE
ZAF
BRA
ARG
CHN
QAT
AUS
IND
DEU
CAN
Merck & Co
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Novartis AG
Inc.
AstraZeneca Plc.
Show more
22:59 28.10.2024
global bile duct cancer market analysis and growth prospects through 2030
United States Dollar
Glaxosmithkline plc
Pfizer Inc.
Novartis AG
Fresenius Kabi AG
AbbVie Inc.
RUS
GBR
ITA
ESP
USA
KOR
SAU
JPN
MEX
ARE
ZAF
BRA
ARG
CHN
QAT
AUS
IND
DEU
CAN
Eli Lilly
GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
AbbVie Inc.
Show more
22:25 28.10.2024
drug stocks poised for earnings surprises in third quarter results
United States Dollar
Pfizer Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
AbbVie Inc.
Merck & Co., Inc.
USA
Eli Lilly
Pfizer Inc.
Bristol Myers Squibb
Merck & Co.
AbbVie Inc.
Show more
17:06 28.10.2024
novartis partners with monte rosa on molecular glue drug development deal
United States Dollar
Pfizer Inc.
Hoffmann-La Roche AG
Novartis AG
Astellas Pharma Inc.
Bristol-Myers Squibb Company
Monte Rosa Therapeutics, Inc.
Fiona Marshall
Markus Warmuth
Show more
12:33 28.10.2024
oncology startup ottimo pharma emerges with innovative dual-pathway cancer drug
Seagen Inc.
Pfizer Inc.
Hoffmann-La Roche AG
BioNTech SE
Bristol-Myers Squibb Company
Merck & Co., Inc.
Mehdi Shahidi
James Sabry
David Epstein
Show more
11:52 28.10.2024
former seagen ceo launches ottimo pharma to combat various cancers
09:30 28.10.2024
Pfizer reports profit growth while CAMS sees significant revenue increase
08:00 28.10.2024
Vaud pharmacists express frustration over low vaccine reimbursement and economic challenges
19:02 25.10.2024
Sanofi reports strong earnings driven by Beyfortus and vaccine sales
United States Dollar
Euro
Sanofi
Merck & Co., Inc.
AstraZeneca PLC
Pfizer Inc.
FRA
USA
Paul Hudson
Show more
17:50 25.10.2024
cdc recommends lowering pneumococcal vaccine age boosting market potential
United States Dollar
Pfizer Inc.
Vaxcyte, Inc.
GSK plc
Merck & Co., Inc.
USA
Daina Graybosch
Roger Song
Akash Tewari
Show more
18:16 24.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Supply Chain Management
Retail and Consumer Goods
Stock Market Updates
Industry Mergers & Acquisitions
Venture Capital Investments
Energy Sector Developments
Finance Mergers & Acquisitions
Cryptocurrency & Blockchain Regulations
Global Financial Events
Central Bank Actions
Emerging Startups
Funding Rounds & Investments
Market Analysis and Predictions
Fintech Startups
Workplace Trends
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Google Inc.
Dell Technologies Inc.
Samsung Securities Co.,Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
XPeng Inc.
Toyota Motor Corp
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
Taiwan Semiconductor Manufacturing Company Limited
Microsoft Corporation
Verizon Communications Inc.
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Currencies:
United States Dollar
Chinese Yuan
Indian Rupee
Euro
Japanese Yen
United Arab Emirates Dirham
British Pound Sterling
Australian Dollar
New Taiwan Dollar
Vietnamese Đồng
New Zealand Dollar
South Korean Won
Egyptian Pound
Thai Baht
Saudi Riyal
Indonesian Rupiah
South African Rand
Malaysian Ringgit
Singapore Dollar
People: